Dr Shuyuan Yao joins Allogene Overland as CEO

Allogene Overland Biopharm, a joint venture created by Overland Pharmaceuticals and Allogene Therapeutics, Inc. has announced the appointment of Shuyuan Yao, Ph.D. as Chief Executive Officer (CEO). Dr Yao brings 15 years of scientific and management experience in advanced cell and gene therapy development, manufacturing and commercialisation to lead Allogene Overland in its mission to bring innovative AlloCAR T therapies to patients in China and other Asian Pacific markets. Most recently, Dr Yao served as Chief Scientific Officer (CSO), Head of Research & Technology Development of WuXi Advanced Therapies at WuXi AppTec where he led new technology acquisition, development, translation and application. Prior to being CSO, Dr Yao served as WuXi Advanced Therapies China General Manager, establishing a new subsidiary company, ATU China. At the start of his tenure at WuXi AppTec Shanghai, he established and directed the Cell Therapy R&D business unit focusing on CAR T cell therapy development. He oversaw the rollout of this business unit to create JW Therapeutics (Shanghai), a joint venture between WuXi AppTec Shanghai and Juno Therapeutics, which was listed on the HKSE in November 2020, serving as VP of Operations.